Long-Term Beneficial Effects of Vanadate, Tungstate, and Molybdate on Insulin Secretion and Function of Cultured Beta Cells

Pancreas

Volumn 28, Issue 4, 2004, Pages 364-368

  Liu, Hui Kang ^a   Green, Brian D ^a   McClenaghan, Neville H ^a   McCluskey, Jane T ^a   Flatt, Peter R ^a  

^a UNIVERSITY OF ULSTER   (United Kingdom)

Author keywords

Insulin; Pancreatic beta cells; Ultratrace elements

Indexed keywords

CYCLIC AMP DEPENDENT PROTEIN KINASE; GLUCOSE; INSULIN; MOLYBDIC ACID; PROTEIN KINASE C; TRACE ELEMENT; TUNGSTIC ACID; UNCLASSIFIED DRUG; VANADIC ACID;

ANIMAL CELL; ARTICLE; CELL CULTURE; CELL FUNCTION; CELL LEVEL; CELL VIABILITY; CONTROLLED STUDY; DESENSITIZATION; DRUG ACTIVITY; DRUG EFFECT; ENZYME ACTIVATION; INSULIN RELEASE; NONHUMAN; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; RAT;

ANIMALS; CELL LINE; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; EXOCYTOSIS; HYPOGLYCEMIC AGENTS; INSULIN; ISLETS OF LANGERHANS; KINETICS; MOLYBDENUM; RATS; TRACE ELEMENTS; TUNGSTEN COMPOUNDS; VANADATES;

EID: 1942475971     PISSN: 08853177     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006676-200405000-00002     Document Type: Article

References (32)

1. Nielsen FH, Uthus EO. The essentiality and metabolism of vanadium. In: Chasteen ND, ed. Vanadium in biological systems-physiology and biochemistry. Dorecht: Kluwer Academic Publishers; 1990:51-62.
2. Thompson KH, Orvig C. Design of vanadium compounds as insulin enhancing agents. J Chem Soc Dalton Trans. 2000;17:2885-2982.
3. Begum N, Sussman KE, Draznin B. Differential effects of diabetes on adipocyte and liver phosphotyrosine and phosphoserine phosphatase activities. Diabetes. 1991;40:1620-1629.
4. Cros GH, Cam MC, Serrano JJ, et al. Long-term antidiabetic activity of vanadyl after treatment withdrawal: restoration of insulin secretion? Mol Cell Biochem. 1995;153:191-195.
5. Li J, Elberg G, Gefel D, et al. Permolybdate and pertungstate-potent stimulators of insulin effects in rat adipocytes: mechanism of action. Biochemistry (Mosc). 1995;34:6218-6225.
6. Munoz MC, Barbera A, Dominguez J, et al. Effects of tungstate, a new potential oral antidiabetic agent, in Zucker diabetic fatty rats. Diabetes. 2001;50:131-138.
7. Bendayan M, Gingras D. Effect of vanadate administration on blood glucose and insulin levels as well as on the exocrine pancreatic function in streptozotocin-diabetic rats. Diabetologia. 1989;32:561-567.
8. Meyerovitch J, Rothenberg P, Shechter Y, et al. Vanadate normalizes hyperglycemia in two mouse models of non-insulin-dependent diabetes mellitus. J Clin Invest. 1991;87:1286-1294.
9. Henquin JC, Carton F, Ongemba LN, et al. Improvement of mild hypoinsulinaemic diabetes in the rat by low non-toxic doses of vanadate. J Endocrinol. 1994;142:555-561.
10. Barbera A, Fernandez-Alvarez J, Truc A, et al. Effects of tungstate in neonatally streptozotocin-induced diabetic rats: mechanism leading to normalization of glycaemia. Diabetologia. 1997;40:143-149.
11. Barbera A, Gomis RR, Prats N, et al. Tungstate is an effective antidiabetic agent in streptozotocin-induced diabetic rats: a long-term study. Diabetologia. 2001;44:507-513.
12. Brichard SM, Okitolonda W. and Henquin, J. C. Long term improvement of glucose homeostasis by vanadate treatment in diabetic rats. Endocrinology. 1988;123:2048-2053.
13. Fantus IG, Tsiani E. Multifunctional actions of vanadium compounds on insulin signaling pathways: evidence for preferential enhancement of metabolic versus mitogenic effects. Mol Cell Biochem. 1998;182:109-119.
14. Woo LC, Yuen VG, Thompson KH, et al. Vanadyl-biguanide complexes as potential synergistic insulin mimics. J Inorg Biochem. 1999;76:251-257.
15. Balasubramanyan M, Mohan V. Orally active insulin mimics: where do we stand now? J Biosci. 2001;26:383-390.
16. Shechter Y, Li J, Meyerovitch J, et al. Insulin-like actions of vanadate are mediated in an insulin-receptor-independent manner via non-receptor protein tyrosine kinases and protein phosphotyrosine phosphatases. Mol Cell Biochem. 1995;153:39-47.
17. Okada Y, Yoshida M, Baba S, et al. Development of vanadate sensitive human erythrocytes insulin receptor tyrosine phosphatase assay. Diabetes Res Clin Pract. 1998;41:157-163.
18. Persaud SJ, Harris TE, Burns CJ, et al. Tyrosine kinases play a permissive role in glucose-induced insulin secretion from adult rat islets. J Mol Endocrinol. 1999;22:19-28.
19. Hwang PL, Ryan RJ. Tungstate stimulates adenylate cyclase. Endocrinology. 1981;108:435-439.
20. Richards JM, Swislocki NI. Mechanism of molybdate activation of adenylate cyclase. Biochim Biophys Acta. 1981;678:180-186.
21. Tan CM, McDonald CG, Chorazyczewski J, et al. Vanadate stimulation of adenylyl cyclase: an index of tyrosine kinase vascular effects. Clin Pharmacol Ther. 1999;66:275-281.
22. Zhang AQ, Gao ZY, Gilon P, et al. Vanadate stimulation of insulin release in normal mouse islets. J Biol Chem. 1991;266:21649-21656.
23. Benes C, Poitout V, Marie JC, et al. Mode of regulation of the extracellular signal-regulated kinases in the pancreatic beta-cell line MIN6 and their implication in the regulation of insulin gene transcription. Biochem J. 1999;340:219-225.
24. Tsiani E, Bogdanovic E, Sorisky A, et al. Tyrosine phosphatase inhibitors, vanadate and pervanadate, stimulate glucose transport and GLUT translocation in muscle cells by a mechanism independent of phosphatidylinositol 3-kinase and protein kinase C. Diabetes. 1998;47:1676-1686.
25. Jonas JC, Henquin JC. Possible involvement of a tyrosine kinase-dependent pathway in the regulation of phosphoinositide metabolism by vanadate in normal mouse islets. Biochem J. 1996;315:49-55.
26. McClenaghan NH, Barnett CR, Ah Sing E, et al. Characterization of a novel glucose-responsive insulin-secreting cell line, BRIN-BD11, produced by electrofusion. Diabetes. 1996;45:1132-1140.
27. Flatt PR, Bailey CJ. Abnormal plasma glucose and insulin responses in heterozygous(ob/+) mice. Diabetologia. 1981;20:573-577.
28. Ferber S, Meyerovitch J, Kriauciunas KM, et al. Vanadate normalizes hyperglycemia and phosphoenolpyruvate carboxykinase mRNA levels in ob/ob mice. Metabolism. 1994;43:1346-1354.
29. Matsumoto J. Vanadate, molybdate and tungstate for orthomolecular medicine. Med Hypotheses. 1994;43:177-182.
30. Daum G, Levkau B, Chamberlain NL, et al. The mitogen-activated protein kinase pathway contributes to vanadate toxicity in vascular smooth muscle cells. Mol Cell Biochem. 1998;183:97-103.
31. Voss C, Herrmann I, Hartmann K, et al. In vitro effect of vanadate on content, secretion and biosynthesis of insulin in isolated islets of normal Wistar rats. Exp Clin Endocrinol. 1992;99:159-163.
32. Pederson RA, Ramanadham S, Buchan AM, et al. Long-term effects of vanadyl treatment on streptozocin-induced diabetes in rats. Diabetes. 1989;38:1390-1395.